Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 10/20 | 0.41 |
| ▸ | JAK2 | O60674 | 6/20 | 0.41 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 5/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 3/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4106152 | 0.85 | NTRK1 (0.52) | NTRK1JAK2NTRK3PTGDR2HCRTR1 | |
| SCHEMBL4301339 | 0.84 | NTRK1 (0.45) | NTRK1JAK2NTRK3HTR2CHTR2A | |
| SCHEMBL18790932 | 0.83 | NTRK1 (0.44) | KCNH2TMEM97SIGMAR1NTRK1JAK2 | |
| SCHEMBL4102308 | 0.83 | JAK2 (0.52) | KCNH2NTRK1JAK2HTR2CHTR2A | |
| SCHEMBL4104895 | 0.83 | SLC6A2 (0.42) | HTR2CHTR2AHTR2B | |
| SCHEMBL23948269 | 0.77 | NTRK1 (0.42) | NTRK1JAK2NTRK3 | |
| SCHEMBL4100964 | 0.77 | NTRK1 (0.42) | NTRK1JAK2NTRK3 | |
| SCHEMBL23032153 | 0.77 | NTRK1 (0.42) | NTRK1JAK2NTRK3 | |
| SCHEMBL4102105 | 0.76 | NTRK1 (0.55) | NTRK1JAK2NTRK3HTR2CHTR2A | |
| SCHEMBL4105109 | 0.75 | OPRM1 (0.39) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796724-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9782415-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9682979-B2 | Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682979-B2 | Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170119770-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170114069-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20150031667-A1 | Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors | ARRAY BIOPHARMA, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8791123-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119770-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | TXK, FRK, LTK | KCNH2 1764/4885TMEM97 2771/4885SIGMAR1 1254/4885 |
| US-20170114069-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | TXK, FRK, LTK | KCNH2 1764/4885TMEM97 2771/4885SIGMAR1 1254/4885 |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | FRK, TXK, TNNI3K | KCNH2 1604/4885TMEM97 2718/4885SIGMAR1 1236/4885 |
| US-20150031667-A1 | Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors | TXK, FRK, LTK | KCNH2 1764/4885TMEM97 2771/4885SIGMAR1 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.